

## LIVERPOOL

The aim of this study was to determine the predictive and/or prognostic value of progastrin, in patients with HCC, before and after curative treatment (surgical resection, radiofrequency ablation) or palliative treatment (transcatheter arterial chemoembolization, targeted therapy, and immunotherapy)

### ***METHODS:***

This study is a prospective cohort monocentric trial in CHU Montpellier.

#### 1- inclusion criteria:

- \* Male or female  $\geq$  18 years old
- \* Histologically confirmed diagnosis HCC
- \* HCC suspected in RMI and/or scanner
- \* In full capacity of their psychological condition, familial, sociological or potentially unfavorable geographical agreement to great study protocol and monitoring program.
- \* Patient information and written informed consent form signed

#### 2- excluded criteria:

- \* Patient with an other cancers in last 5 years
- \* Current infection
- \* Patient with autoimmune disease (as lupus, IBD, scleroderma, ...)
- \* top athlete

#### 3- Methods :

The assay is performed from a fasting blood sample in EDTA tube (2 test tubes of 7 mL per sample).

The samples will be transferred to Biochemical department for anonymization, centrifugation (2000g during 15 minutes) and freezing (- 80°C).

The biobank was declared since 2014 december at CHU Montpellier (n° BB-0033-00031).

#### 4- Monitoring

The biobank opening after once the relevant ethics committee has given its authorisation (N° 2019\_IRB-MTP\_01-11- MR004)

Patient follow up is every 2 month until death.